利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.015 秒)

    Container for the controlled administration of a beneficial agent
    8.
    发明授权
    Container for the controlled administration of a beneficial agent 失效
    用于受控管理有益药剂的容器

    公开(公告)号：US5304130A

    公开(公告)日：1994-04-19

    申请号：US841957

    申请日：1992-02-26

    申请人： Kathryn M. Button ,  Steven C. Jepson ,  Birendra K. Lal ,  Douglas W. Reitz ,  James Richardson ,  Richard A. Rollins ,  Paul J. Soltys ,  Thomas E. Dudar

    发明人： Kathryn M. Button ,  Steven C. Jepson ,  Birendra K. Lal ,  Douglas W. Reitz ,  James Richardson ,  Richard A. Rollins ,  Paul J. Soltys ,  Thomas E. Dudar

    IPC分类号： A61M39/02 ,  A61M5/14 ,  A61M37/00

    CPC分类号： A61M5/1409

    摘要： A container for housing a beneficial agent that can be removably coupled to a structure defining a fluid flow path. The container comprises a body defining a first and second interior area separated by a wall that terminates at an opening providing fluid communication between the first and second interior area. A cannula is provided that extends from the body for being removably received by the structure defining the fluid path. The cannula includes an inlet opening and inlet fluid flow path and an outlet opening and outlet fluid flow path. The inlet fluid flow path being in fluid communication with the first interior area, and the outlet fluid flow path being in fluid communication with the second interior area. The second interior area houses the solid beneficial agent and allows fluid that flows through the inlet fluid flow path to pass by at least a portion of the beneficial agent.

    摘要翻译： 用于容纳有益剂的容器，其可拆卸地联接到限定流体流路的结构。 容器包括主体，其限定由墙壁分隔开的第一和第二内部区域，该第一和第二内部区域终止于提供第一和第二内部区域之间的流体连通的开口。 提供了一种套管，其从主体延伸以便被限定流体路径的结构可移除地容纳。 套管包括入口开口和入口流体流动路径以及出口开口和出口流体流动路径。 入口流体流动路径与第一内部区域流体连通，并且出口流体流动路径与第二内部区域流体连通。 第二内部区域容纳固体有益剂并且允许流过入口流体流动路径的流体通过有益剂的至少一部分。

    Oral bilirubin therapy
    9.
    发明授权
    Oral bilirubin therapy 失效
    口服胆红素治疗

    公开(公告)号：US5200181A

    公开(公告)日：1993-04-06

    申请号：US593345

    申请日：1990-10-01

    申请人： Paul J. Soltys ,  Claudy J. P. Mullon ,  Robert S. Langer

    发明人： Paul J. Soltys ,  Claudy J. P. Mullon ,  Robert S. Langer

    IPC分类号： A61K38/44 ,  A61K38/45

    CPC分类号： A61K38/45 ,  A61K38/44 ,  A61K47/4823 ,  A61K47/48853 ,  A61K9/0053 ,  C12Y103/03005 ,  C12Y204/01017

    摘要： Levels of bilirubin in mammalian serum are controlled by administering to the mammalian intestinal tract a substance (a "bilirubin deactivator") that converts unconjugated bilirubin into nontoxic, physiologically compatible products, thereby reducing reabsorption of unconjugated bilirubin in enterohepatic circulation. Useful bilirubin deactivators include those which specifically adsorb the bilirubin and are excreted, and "bilirubin conversion enzymes", i.e., enzymes that operate on the unconjugated bilirubin substrate to yield products that are physiologically compatible in that they are not reabsorbed, or, if reabsorbed, they are nontoxic in the blood stream.

    摘要翻译： 哺乳动物血清中的胆红素水平通过向哺乳动物肠道施用将未结合的胆红素转化为无毒的生理相容产物的物质（“胆红素失活剂”）来控制，从而减少未结合的胆红素在肠肝循环中的再吸收。 有用的胆红素减活剂包括特异性吸附胆红素并被排泄的那些，以及“胆红素转化酶”，即在非共轭胆红素底物上操作以产生生理上相容的产物，因为它们不被再吸收，或者如果被再吸收， 它们在血液中无毒。